Changes in Hong Kong stocks | Zaiding Pharmaceutical (09688) rose more than 7%, Q2 product revenue increased 11% month-on-month, Citi is optimistic that China's business will stabilize in the second half of the year

Zhitongcaijing · 3d ago

The Zhitong Finance App learned that Zaiding Pharmaceutical (09688) rose more than 7% in the intraday period. As of press release, it had risen 5.68% to HK$18.6, with a turnover of HK$185 million.

According to the news, Zaiding Pharmaceutical recently announced financial results for the second quarter of 2026, as well as recent product highlights and company progress. According to financial reports, the company's total revenue for the second quarter of 2026 was US$106.3 million, and net product revenue was US$105.8 million, up 11% month-on-month, thanks to Zelle's steady performance and the continued growth of Agamod's sales. Dr. Du Ying, founder of Zaiding Pharmaceutical, said that the company has gradually grown into a global biopharmaceutical company developing our own differentiated medicines for patients around the world.

According to a report published by Citigroup, Zaiding Pharmaceutical's product revenue for the second quarter improved by about 11% quarterly to about US$106 million, which is in line with the bank and market expectations, making the bank more confident that its business in China can stabilize in the second half of 2026 and resume significant growth in 2027 in accordance with management guidelines. According to the bank, the focus is increasingly turning to upcoming pipeline catalysts, and continues to view zoci as the main value driver.